Setmelanotide for the Treatment of LEPR Deficiency Obesity
Status:
Completed
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
This study is assessing the effect of setmelanotide (RM-493) on weight and other factors in
patients with Leptin Receptor (LEPR) deficiency obesity due to rare bi-allelic
loss-of-function LEPR genetic mutation.